CD8A and non-small cell lung carcinoma: Immune checkpoint blockade that activates CD8 + T cells is the standard of care for patients with metastatic non-small cell lung cancer (NSCLC) lacking actionable genomic alterations (such as EGFR and ALK alterations) [1, 2].